Connections
Work with your personal adviser to grow your wealth
Jeremy Sullivan

US Federal Reserve Rate Rise. NZ GDP disappoints. Fonterra result, what to expect- Market Talk with Jeremy Sullivan

Jeremy Sullivan dicusses this weeks main topics on the New Zealand sharemarket, joining him, Andrew Patterson from the National Business Review.
Filed under Jeremy Sullivan \ NBR

Market Talk with Jeremy Sullivan. NZX Market Sentiment, Earnings Season, Trump - AUDIO FEATURE

Jeremy Sullivan talks to Andrew Patterson of the National Business Review regarding the upcoming earnings season on the NZX and which stocks to watch. Also, how is the market sentiment tracking enlight of the new administration in the US, and more... Click below to listen
Filed under Jeremy Sullivan \ NBR

CNBC's Squawk Box talks to Jeremy Sullivan regarding the New Zealand Bond Market

Investors yearning higher yields while keeping a lid on risks have had a hard time of late. One investor says New Zealand debt may come to the rescue. U.S. Treasurys have long been a safe haven asset, but a sharp plunge in yields has pushed investors to search elsewhere. Recent Treasury International Capital (TIC) data revealed foreign investors dumped nearly $33 billion dollars in U.S. paper for the third straight month in June, begging the question of where market players...

NZX continues rally ahead of expected OCR cut - Audio Feature - NBR Radio

New Zealand’s stock market continues to rally ahead of tomorrow morning’s much-anticipated official cash rate (OCR) announcement. The S&P NZX 50 is up 0.3% this week, with the gross index gaining 5.07% in the last 31 days and more than 21% so far this year. Hamilton Hindin Greene investment adviser Jeremy Sullivan says the gains have been, in large part, because of the Reserve Bank lowering the OCR and changing its sentiment at the end of last year. The market...

Upcoming Investor Presentation - 20th October 2016 - Ryman - EBOS - Metlifecare

HHG is proud to be hosting Chief Executives, Chief Financial Officers and Management from some of New Zealand's largest listed companies. Ryman Healthcare, EBOS Group and Metlifecare. The Investor Presentation which is to be held on the 20th of October 2016 at 9:30am through to 11:00am, at the newly built function centre of the Sudima Hotel, Christchurch Airport, followed by refreshments. If you would like to attend please RSVP by Thursday the 13th October at the latest. Seats are limited and...

Brexit - Should they stay or should they go?

On the 23rd of June 2016, Britain will vote on whether to stay within the European Union (EU). What does it all mean? What does it mean for Europe, the UK and the World? What does it mean for your portfolio? Firstly, what is “Brexit”? What is it? Brexit is an abbreviation of "British exit" that mirrors the term Grexit. It refers to the possibility that Britain will withdraw from the European Union. The country will hold an in-out referendum...

Will New Zealand's central bank cut rates further?

Jeremy Sullivan talks to CNBC Asia regarding the NZX, interest rates and the outlook for 2016 Click here to view the video

Pacific Edge - Internationalising the Entrepreneurial Firm

Pacific Edge Ltd is a NZX listed [PEB.NZX], New Zealand based biotechnology firm, specialising in the field of bladder cancer detection, through their primary product suite called ‘CX-Bladder’. The technology has been derived from the University of Otago and was established in 2001. The primary competitive advantage of the CX-Bladder product suite; is the non-invasive (urine) testing and their market leading diagnostic accuracy, compared to other urine based testing. The incumbent diagnostic tool is cystoscopy, which involves having a narrow tube...
Page 1
Find An Advisor CONTACT NOW
Become A Client START NOW